Previous close | 19.40 |
Open | 19.40 |
Bid | 21.60 |
Ask | 21.90 |
Strike | 85.00 |
Expiry date | 2024-06-21 |
Day's range | 19.40 - 19.40 |
Contract range | N/A |
Volume | |
Open interest | 866 |
FOSTER CITY, Calif., June 05, 2024--Gilead Sciences, Inc. (Nasdaq: GILD), following the recent acquisition of CymaBay Therapeutics, Inc., today announced two-year interim results from the ongoing ASSURE study of investigational seladelpar for the treatment of primary biliary cholangitis (PBC), a rare, chronic inflammatory liver disease. The two-year interim analysis includes people living with PBC who participated in any prior clinical studies of seladelpar (legacy studies) and participants from
NextEra Energy, BP, Gilead Sciences, Hamilton Beach and FONAR are part of the Zacks top Analyst Blog.
We recently compiled a list of the 9 Best Gene Therapy Stocks to Buy Now and in this article, we discuss Gilead Sciences, Inc. (NASDAQ:GILD), which is one of the best gene therapy stocks to buy now. Gene therapy involves treating illnesses by modifying, replacing, or supplementing faulty or missing genes responsible for a disease. […]